PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1102206
PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1102206
The global pterygium drug market is projected to register a substantial CAGR of 6.2% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2020, the base year of calculation is 2021, and the forecast period is 2022 to 2029.
Global Pterygium Drug Market, By Type (Progressive Pterygium and Atrophic Pterygium), Stages (Stage 2, Stage 3, Stage 1, Stage 4), Treatment (Artificial Tears/Topical Lubricants and Steroid Eye Drops.), Formulation (Eye Drops, Eye Ointments, Others), Mode of Purchase (Prescription and Over the Counter (OTC)), Population Type (Geriatric and Adults), End-User (Hospitals, Specialty Clinics, Home Healthcare, Others), Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies, Others), Region (North America, Europe, Asia-Pacific, South America, Middle East, and Africa) Industry Trends and Forecast to 2029
Increase in healthcare awareness to reduce the risk of eye illnesses
Rising geriatric population
Johnson & Johnson Services, Inc.
Novartis AG
Akorn Operating Company LLC
Bausch & Lomb Incorporated
AbbVie Inc.
Prestige Consumer Healthcare Inc.
Spectra Vision Care,
Thea Laboratories
Wellona Pharma
SAGER PHARMA
Maya Biotech Private Limited
EYERIS VISIONCARE Pvt. Ltd.
Sylentis
Bayer AG
Zydus Group
Amneal Pharmaceuticals LLC
OASIS Medical
Similasan Corporation
Alcon
Santen Pharmaceutical Co.